Filtered By:
Condition: Thrombosis
Procedure: Heart Transplant
This page shows you your search results in order of date.
Order by Relevance | Date
Total 180 results found since Jan 2013.
Detection of inflow obstruction in left ventricular assist devices by accelerometer: A porcine model study
Left ventricular assist devices (LVAD) provide circulatory blood pump support for severe heart failure patients. Pump inflow obstructions may lead to stroke and pump malfunction. We aimed to verify in vivo that gradual inflow obstructions, representing prepump thrombosis, are detectable by a pump-attached accelerometer, where the routine use of pump power (PLVAD) is deficient.
Source: The Journal of Heart and Lung Transplantation - April 4, 2023 Category: Transplant Surgery Authors: Didrik Lilja, Itai Schalit, Andreas Espinoza, Arnt Eltvedt Fiane, Gry Dahle, Helen Littorin-Sandbu, Fred-Johan Pettersen, Kristoffer Engh Russell, Amrit Paul Singh Thiara, Ole Jakob Elle, Per Steinar Halvorsen Tags: Original Pre-Clinical Science Source Type: research
Colocutaneous Fistula Following Pediatric Bivad Implantation, A Rare but Serious Complication
We present 2 patients who had rare colocutaneous fistulas associated with Berlin Heart EXCOR ® placement.
Source: The Journal of Heart and Lung Transplantation - April 1, 2023 Category: Transplant Surgery Authors: S. Rangu, J. Murray, A. Shiu, E. Martin, T. Nasirov, M. Bruzoni, S. Chen, D. Rosenthal, M. Ma, J. Dykes Tags: (1035) Source Type: research
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Identifying patients at risk: multi ‐centre comparison of HeartMate 3 and HeartWare left ventricular assist devices
ConclusionsHM3 patients have a significantly better survival and a lower incidence of ischaemic strokes and pump thrombosis than HVAD patients. This survival difference persisted after 2 years of implantation. Additional research using post-operative variables is warranted to identify which HVAD patients need an upgrade to HM3 or expedited transplantation.
Source: ESC Heart Failure - February 17, 2023 Category: Cardiology Authors: Lieke Numan,
Daniel Zimpfer,
Osnat Itzhaki Ben Zadok,
Emmeke Aarts,
Michiel Morshuis,
Sabina P.W. Guenther,
Julia Riebandt,
Dominik Wiedemann,
Faiz Z. Ramjankhan,
Anne ‐Marie Oppelaar,
Tuvia Ben‐Gal,
Binyamin Ben‐Avraham,
Folkert W. Asse Tags: Original Article Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Contemporary Mechanical Circulatory Support With Continuous-Flow Biventricular Assist Devices: A Systematic Review
As the incidence of heart failure increases, so too has that of biventricular failure. While transplantation remains the gold standard therapy for end-stage heart failure, the limited organ supply has increased the need for durable mechanical circulatory support. We therefore sought to conduct a systematic review of continuous-flow ventricular assist devices in a biventricular configuration (CF-BiVAD). An electronic search of PubMed and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases was performed using the keyword “BIVAD.” Studies were reviewed to identify discrete variables, including impl...
Source: Cardiology in Review - June 10, 2022 Category: Cardiology Tags: Review Articles Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Advancements in left ventricular assist devices to prevent pump thrombosis and blood coagulopathy
J Anat. 2022 Apr 20. doi: 10.1111/joa.13675. Online ahead of print.ABSTRACTMechanical circulatory support (MCS) devices, such as left ventricular assist devices (LVADs) are very useful in improving outcomes in patients with advanced-stage heart failure. Despite recent advances in LVAD development, pump thrombosis is one of the most severe adverse events caused by LVADs. The contact of blood with artificial materials of LVAD pumps and cannulas triggers the coagulation cascade. Heat spots, for example, produced by mechanical bearings are often subjected to thrombus build-up when low-flow situations impair washout and thus th...
Source: Journal of Anatomy - April 21, 2022 Category: Anatomy Authors: Grainne Malone Gerges Abdelsayed Fianait Bligh Fatma Al Qattan Saifullah Syed Prateepan Varatharajullu Augustin Msellati Daniela Mwipatayi Maimoona Azhar Andrew Malone Saulat H Fatimi Claire Conway Aamir Hameed Source Type: research
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Computational Investigation of Outflow Graft Variation Impact on Hemocompatibility Profile in LVADs
This study, used a simulation-based approach to investigate the influence that the cannula orientation has in modulating flow conditions leading to HRAEs.
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: B.A. Zambrano, S. Ingram, M.R. Moreno, M. Kassi Tags: (1161) Source Type: research
Stroke and Pump Thrombosis Following LVAD Implantation: The Impact of the Implantation Approach
The aim of this study is to investigate the impact of LVAD (left ventricular assist device) implantation technique on long-term mortality and morbidity, with special focus on stroke and pump thrombosis.
Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: M. Nozdrzykowski Tags: (650) Source Type: research
Bacteriophage Therapy and the Biofilm: An Old Solution for a Persistent and Desperate Problem?
With the adoption of use of continuous-flow pumps with centrifugal design and complete magnetic levitation (i.e., HeartMate 3, Abbott, Chicago, IL), outcomes following durable left ventricular assist device (LVAD) have continuously improved over the last five years (1). Improved hemocompatibility associated with this device design has translated into a significant reduction in major adverse events, primarily pump thrombosis, stroke, and to a lesser extent, reduction in non-surgical bleeding (1).
Source: The Journal of Heart and Lung Transplantation - February 14, 2022 Category: Transplant Surgery Authors: Pierre-Emmanuel Noly, Francis D. Pagani Tags: Editorial Source Type: research
